Cardinal Health ( (CAH) ) has released its Q3 earnings. Here is a breakdown of the information Cardinal Health presented to its investors.
Cardinal Health is a leading healthcare services and products company, specializing in the distribution of pharmaceuticals and medical products, as well as offering performance and data solutions. The company operates globally, focusing on improving healthcare efficiency and patient outcomes.
In its third quarter fiscal year 2025 earnings report, Cardinal Health reported stable revenues of $54.9 billion, with a significant 19% increase when excluding the impact of a previous customer contract expiration. The company also raised its fiscal year 2025 earnings guidance, reflecting strong financial performance across its segments.
Key financial highlights include a 98% increase in GAAP operating earnings to $730 million and a 21% rise in non-GAAP operating earnings to $807 million. The Pharmaceutical and Specialty Solutions segment remained stable in revenue but saw a 14% increase in profit, while the Global Medical Products and Distribution segment experienced a 2% revenue growth and a 77% profit increase. The Other segment also showed robust growth with a 13% revenue increase and a 22% profit rise.
Looking ahead, Cardinal Health has raised its non-GAAP EPS guidance for fiscal year 2025, indicating confidence in continued growth and resilience. The company anticipates double-digit non-GAAP EPS growth in fiscal 2026, driven by strong performance in its Pharmaceutical and Specialty Solutions segment and other operating segments.
With strategic expansions and acquisitions, such as the entry into the urology therapeutic area and the acquisition of Advanced Diabetes Supply Group, Cardinal Health is well-positioned to enhance its service offerings and maintain its momentum in the healthcare sector.